Rigel Pharmaceuticals (RIGL) Cash from Operations (2010 - 2026)

Rigel Pharmaceuticals' Cash from Operations history runs 17 years deep, the most recent figure standing at 2725000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 405.15% year-over-year to 2725000.0; the TTM figure through Mar 2026 stood at 79273000.0 (up 122.73% YoY), while the FY2025 annual figure was 75655000.0, up 140.4% from the prior year.
• Cash from Operations for Q1 2026 stood at 2725000.0, down from 21980000.0 in the prior quarter.
• The five-year high for Cash from Operations was 30537000.0 in Q2 2025, with the low at 25637000.0 in Q1 2022.
• The 5-year median for Cash from Operations is 893000.0 (2025), against an average of 1785294.12.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations plunged 123.38% in 2022, then surged 10011.59% in 2025.
• Rigel Pharmaceuticals' Cash from Operations stood at 21909000.0 in 2022, then jumped by 71.52% to 6240000.0 in 2023, then surged by 332.42% to 14503000.0 in 2024, then soared by 51.55% to 21980000.0 in 2025, then tumbled by 87.6% to 2725000.0 in 2026.
• Business Quant data shows RIGL's Cash from Operations at 2725000.0 in Q1 2026, 21980000.0 in Q4 2025, and 24031000.0 in Q3 2025.